Advice
following a full submission:
boceprevir (Victrelis®) is accepted for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon and ribavirin, in adult patients with compensated liver disease who are previously untreated.
In the pivotal, phase III randomised study, addition of boceprevir to current standard therapy in patients with HCV who were previously untreated increased the proportion of patients with HCV who achieved a sustained virologic response.
Download detailed advice144KB (PDF)
Medicine details
- Medicine name:
- boceprevir (Victrelis) Naive Patients
- SMC ID:
- 723/11
- Indication:
- Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon and ribavirin, in adult patients with compensated liver disease who are previously untreated.
- Pharmaceutical company
- MSD
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 October 2011